Bio-Rad Laboratories Class A
470 hedge funds and large institutions have $8.03B invested in Bio-Rad Laboratories Class A in 2022 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 212 increasing their positions, 132 reducing their positions, and 61 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 212 | Existing positions reduced: 132
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
1% less capital invested
Capital invested by funds: $8.13B → $8.03B (-$104M)
8% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 61
2.05% less ownership
Funds ownership: 79.1% → 77.04% (-2.1%)
3% less funds holding
Funds holding: 484 → 470 (-14)
35% less call options, than puts
Call options by funds: $46.2M | Put options by funds: $70.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$73.6M |
| 2 |
VAM
Veritas Asset Management
London,
United Kingdom
|
+$62.8M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$35.9M |
| 4 |
Amundi
Paris,
France
|
+$31.6M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$30.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$165M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$85M |
| 3 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$81.3M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$69.4M |
| 5 |
Millennium Management
New York
|
-$57.9M |
BIO Hedge Fund Activity: Q4 2022 in Review
470 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q4 2022, worth a combined $8.03B — down 1.3% from $8.13B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of BIO and 56 opened new positions — a net loss of 5 holders — while 132 trimmed existing stakes and 212 added.
The largest buyer was Thompson Siegel & Walmsley, adding an estimated $73.6M. The largest seller was Fidelity Investments, cutting an estimated $165M.
- 470 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q4 2022, down from 484 in Q3 2022.
- Funds reported $8.03B of Bio-Rad Laboratories Class A stock for Q4 2022, down 1.3% quarter-over-quarter.
- 56 funds opened new Bio-Rad Laboratories Class A positions in Q4 2022 and 61 closed out, a net change of -5 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q4 2022 was Thompson Siegel & Walmsley, an estimated $73.6M added.
- The largest Bio-Rad Laboratories Class A seller in Q4 2022 was Fidelity Investments, an estimated $165M sold.
Based on aggregated 13F filings for Q4 2022.